  DelSite Biotechnologies, Inc. (Irving, TX, 

), a wholly-owned subsidiary  of Carrington Laboratories, Inc. (Irving, TX, 

), has entered  into a non-exclusive technology evaluation agreement with Nastech  Pharmaceutical Company, Inc. (Bothell, DC, 

),  for the purpose of evaluating DelSite's GelSite polymer for enhancing the  intranasal delivery of peptide and protein therapeutics. Financial terms of the  agreement were not disclosed.

GelSite polymer is a novel, naturally occurring,  mucoadhesive ionic carbohydrate polymer capable of forming a gel when brought  into contact with nasal fluids. Gelling occurs with liquid as well as powder  formulations and provides sustained release and prolonged nasal residence time  that may enhance the nasal delivery of therapeutics or vaccines.

DelSite has evaluated GelSite polymer for delivery of  various protein and peptide therapeutics and vaccine antigens and has completed  a series of toxicology studies on this polymer. A drug master file (DMF) for  use of GelSite polymer in mucosal applications was filed in 2005 and was  recently updated with both CBER and CDER.

News

DelSite Biotechnologies, Inc. (Irving, TX, www.delsite.com), a wholly-owned subsidiary of Carrington Laboratories, Inc. (Irving, TX, www.carringtonlabs.com), has entered into a non-exclusive technology evaluation agreement with Nastech Pharmaceutical Company, Inc. (Bothell, DC, www.nastech.com), for the purpose of evaluating DelSite's GelSite polymer for enhancing the intranasal delivery of peptide and protein therapeutics.